The world at a glance
- Population
- 8.22 billion 2025
- Life expectancy at birth
- 73.5 years, 2024
- People aged 65 and over
- 10.4 % of people, 2025
- Health spending per person
- 1,317 US$ per person, 2023
- Doctors
- 1.86 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Global Preclinical CRO Market Industry Trends and Forecast to 2034: Segmented by (Service, Model, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.35 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $6.54 Bn | — | — |
| 2025 (base) | $7.13 Bn | +$588.6 Mn | — |
| 2026 (forecast) | $7.77 Bn | +$641.6 Mn | +9% |
| 2027 (forecast) | $8.47 Bn | +$699.3 Mn | +18.8% |
| 2028 (forecast) | $9.23 Bn | +$762.3 Mn | +29.5% |
| 2029 (forecast) | $10.06 Bn | +$830.9 Mn | +41.2% |
| 2030 (forecast) | $10.97 Bn | +$905.6 Mn | +53.9% |
| 2031 (forecast) | $11.96 Bn | +$987.1 Mn | +67.7% |
| 2032 (forecast) | $13.03 Bn | +$1.08 Bn | +82.8% |
| 2033 (forecast) | $14.20 Bn | +$1.17 Bn | +99.3% |
| 2034 (forecast) | $15.48 Bn | +$1.28 Bn | +117.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $7.13 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $15.48 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Service and model (see all) |
| Key players | Charles River Laboratories, Labcorp, WuXi AppTec, Eurofins Scientific, Inotiv and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Preclinical contract research organizations run lab and animal studies on new drugs for safety and effect before they are tested in people.
Key segments of the preclinical CRO market include service (Toxicology Testing, Bioanalysis and Pharmacology) and model (In Vivo, In Vitro and In Silico).
Drug makers are outsourcing more research, the pipeline of new drugs is growing and small biotech firms need partners with lab and trial skills, which drives the preclinical CRO market.
Data-driven trial design, new drug types such as cell and gene therapy and demand from Asian drug makers give the preclinical CRO market room to grow.
Pressure on prices, difficulty finding trial patients and staff turnover at service firms hold back the preclinical CRO market.
The preclinical CRO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.[1]
[1] World Health Organization, universal health coverage. Checked 14 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how preclinical CRO services are delivered and paid for in Global. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Preclinical CRO right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Pharmaceuticals · Global
Digital Health · Global
Pharmaceuticals · Global
Digital Health · Global
Digital Health · Global
Pharmaceuticals · Global